This inventor holds 2 USPTO granted patents. Top assignee: Glaxo Group Limited. Active years: 1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999
Title: Barry Edward Ayres: A Legacy of Innovation
Introduction
Barry Edward Ayres was a notable inventor whose contributions to the field of biochemistry have left a lasting impact. He was based in Hitchin, GB, and held a total of 2 patents during his career. His work primarily focused on the development of novel compounds that have potential applications in medicine.
Latest Patents
Among his latest patents are the inventions of 2,6-Di(substitutedamino) purine ribonucleoside analogues and 2,6-diaminopurine precursors. These inventions relate to compounds of formula (IV), wherein R.sup.a and R.sup.b each represent a hydrogen atom or together form an alkylidene group. These innovations demonstrate his expertise in creating compounds that could advance therapeutic options.
Career Highlights
Barry Edward Ayres was associated with Glaxo Group Limited, where he contributed significantly to research and development. His work in the pharmaceutical industry was marked by a commitment to innovation and excellence. His inventions have been recognized for their potential to improve health outcomes.
Collaborations
Throughout his career, Barry collaborated with notable colleagues, including Michael Gregson and George B Ewan. These partnerships were instrumental in advancing his research and expanding the scope of his inventions.
Conclusion
Barry Edward Ayres was a dedicated inventor whose work in biochemistry has had a profound influence on the field. His patents and collaborations reflect a commitment to innovation that continues to inspire future generations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile